Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study
To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung cancer.
Lung Cancer
Disease Control Rates (DCR), Lung lesions of disease control rates DCR (CR + PR + SD), according to solid tumor response evaluation standard (response evaluation criteria in solid tumors, RECIST) standard, From 12-2011 to 12-2013
Overall Survival(OS), Disease progression-free surial (Progression-Free Srvival, PFS) with observations, 2 years
A randomized controlled trail on the efficacy and safety of autologous cytokine-induced killer (CIK) cells infusion treatment in advanced primary lung cancer